DK474688A - Praeparat til bekaempelse af tumor eller kraeftceller - Google Patents
Praeparat til bekaempelse af tumor eller kraeftcellerInfo
- Publication number
- DK474688A DK474688A DK474688A DK474688A DK474688A DK 474688 A DK474688 A DK 474688A DK 474688 A DK474688 A DK 474688A DK 474688 A DK474688 A DK 474688A DK 474688 A DK474688 A DK 474688A
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- tumor
- administration
- radiation
- compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 abstract 1
- 102000000584 Calmodulin Human genes 0.000 abstract 1
- 108010041952 Calmodulin Proteins 0.000 abstract 1
- 108010077544 Chromatin Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 abstract 1
- 230000005880 cancer cell killing Effects 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 230000004637 cellular stress Effects 0.000 abstract 1
- 210000003483 chromatin Anatomy 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 abstract 1
- 229960004503 metoclopramide Drugs 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 150000002990 phenothiazines Chemical class 0.000 abstract 1
- 230000005909 tumor killing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8947787A | 1987-08-25 | 1987-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK474688D0 DK474688D0 (da) | 1988-08-25 |
| DK474688A true DK474688A (da) | 1989-02-26 |
Family
ID=22217866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK474688A DK474688A (da) | 1987-08-25 | 1988-08-25 | Praeparat til bekaempelse af tumor eller kraeftceller |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5340565A (da) |
| EP (1) | EP0305008B1 (da) |
| JP (1) | JP2767590B2 (da) |
| AT (1) | ATE106749T1 (da) |
| AU (1) | AU622118B2 (da) |
| CA (1) | CA1336409C (da) |
| DE (1) | DE3850007T2 (da) |
| DK (1) | DK474688A (da) |
| ES (1) | ES2056902T3 (da) |
| IE (1) | IE63858B1 (da) |
| IL (1) | IL87525A (da) |
| RU (1) | RU2080115C1 (da) |
| ZA (1) | ZA885929B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1247937B (it) * | 1991-05-16 | 1995-01-05 | Ist Naz Ric Sul Cancro | Associazione farmaceutica ad attivita' antineoplastica |
| IT1252126B (it) * | 1991-11-22 | 1995-06-05 | Ist Naz Ric Sul Cancro | Triamino platino complessi e loro metodo di sintesi |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5624902A (en) * | 1995-06-07 | 1997-04-29 | Torrey Pines Institute For Molecular Studies | Peptide inhibitors of calmodulin |
| US6056960A (en) * | 1995-06-07 | 2000-05-02 | Kaslow; Harvey R. | Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof |
| US6028111A (en) * | 1996-03-08 | 2000-02-22 | Oxigene, Inc. | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents |
| US6713517B1 (en) * | 1996-03-08 | 2004-03-30 | Oxigene, Inc. | Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use |
| WO1998035677A1 (en) * | 1997-02-18 | 1998-08-20 | Bridge Pharma, Inc. | Non-sedating histamine antagonist compounds, compositions and methods of use thereof |
| US6074626A (en) * | 1998-03-20 | 2000-06-13 | Molecular Radiation Management, Inc. | Radioactive cisplatin in the treatment of cancer |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6573050B1 (en) | 1999-10-29 | 2003-06-03 | Sunnybrook & Women's College Health Sciences Centre | Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma |
| US6448288B1 (en) * | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| US20040072825A1 (en) * | 2000-12-19 | 2004-04-15 | Yves Lamberty | 2-(2-(4-((2r)-2-methyl-3-(10h-phenothiazin-10-yl)propyl)-1-piperazinyl)-ethoxy) ethanol, process for the preparation thereof, pharmaceutical compositions containing said compound and therapeutic uses thereof |
| FR2825279B1 (fr) * | 2001-06-01 | 2005-04-08 | Molecular Engines Lab | Medicament utile dans le traitement du cancer |
| US7547716B2 (en) | 2001-06-08 | 2009-06-16 | Institute Of Medicinal Molecular Design, Inc. | Sulfonamide derivatives |
| RU2236848C1 (ru) * | 2003-02-25 | 2004-09-27 | Государственный научный центр - Институт биофизики | Средство, уменьшающее токсичность противоопухолевых препаратов |
| RU2228752C1 (ru) * | 2003-03-21 | 2004-05-20 | Государственный научный центр - Институт биофизики | Фармацевтическая композиция, содержащая ондансетрон и бензамид |
| RU2275920C1 (ru) * | 2005-04-01 | 2006-05-10 | Игорь Анатольевич Помыткин | Способ лечения новообразований |
| US20100055183A1 (en) * | 2008-08-28 | 2010-03-04 | Osteogenex Inc. | Trimeprazine and ethopropazine derivatives for promoting bone growth |
| FR2970965A1 (fr) * | 2011-01-31 | 2012-08-03 | Centre Nat Rech Scient | Composes anti-angiogeniques, compositions pharmaceutiques les comprenant, et leur utilisation |
| WO2013138101A2 (en) | 2012-03-16 | 2013-09-19 | Children's Medical Center Corporation | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536386B1 (en) * | 1981-01-26 | 1995-03-07 | Robins Co Inc A H | Method of controlling emesis caused by cisplatin in cancer chemotherapy |
| US5081153A (en) * | 1984-05-17 | 1992-01-14 | Beecham Group P.L.C. | Sterile parenteral composition |
-
1988
- 1988-08-11 ZA ZA885929A patent/ZA885929B/xx unknown
- 1988-08-15 IE IE248788A patent/IE63858B1/en not_active IP Right Cessation
- 1988-08-22 IL IL8752588A patent/IL87525A/en not_active IP Right Cessation
- 1988-08-24 CA CA000575624A patent/CA1336409C/en not_active Expired - Fee Related
- 1988-08-24 EP EP88201795A patent/EP0305008B1/en not_active Expired - Lifetime
- 1988-08-24 RU SU884356575A patent/RU2080115C1/ru active
- 1988-08-24 DE DE3850007T patent/DE3850007T2/de not_active Expired - Fee Related
- 1988-08-24 AU AU21508/88A patent/AU622118B2/en not_active Ceased
- 1988-08-24 ES ES88201795T patent/ES2056902T3/es not_active Expired - Lifetime
- 1988-08-24 AT AT88201795T patent/ATE106749T1/de not_active IP Right Cessation
- 1988-08-25 JP JP63212320A patent/JP2767590B2/ja not_active Expired - Fee Related
- 1988-08-25 DK DK474688A patent/DK474688A/da not_active Application Discontinuation
-
1992
- 1992-06-10 US US07/896,236 patent/US5340565A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL87525A (en) | 1994-05-30 |
| ES2056902T3 (es) | 1994-10-16 |
| DE3850007T2 (de) | 1994-09-22 |
| JPH0196122A (ja) | 1989-04-14 |
| RU2080115C1 (ru) | 1997-05-27 |
| AU2150888A (en) | 1989-03-02 |
| IE63858B1 (en) | 1995-06-14 |
| EP0305008A2 (en) | 1989-03-01 |
| EP0305008A3 (en) | 1990-05-16 |
| IL87525A0 (en) | 1989-01-31 |
| CA1336409C (en) | 1995-07-25 |
| ZA885929B (en) | 1989-04-26 |
| DE3850007D1 (de) | 1994-07-14 |
| IE882487L (en) | 1989-02-25 |
| JP2767590B2 (ja) | 1998-06-18 |
| DK474688D0 (da) | 1988-08-25 |
| ATE106749T1 (de) | 1994-06-15 |
| EP0305008B1 (en) | 1994-06-08 |
| AU622118B2 (en) | 1992-04-02 |
| US5340565A (en) | 1994-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK474688A (da) | Praeparat til bekaempelse af tumor eller kraeftceller | |
| Hansen et al. | The variability of individual tolerance to methotrexate in cancer patients | |
| EA200500893A1 (ru) | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии | |
| MX9206577A (es) | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES | |
| DE3376295D1 (en) | Pharmaceutical composition containing adenosine derivatives for use in treating tumours | |
| ES2056190T3 (es) | Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa. | |
| ATE242635T1 (de) | Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren | |
| SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
| MX9703621A (es) | Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples. | |
| KR900701282A (ko) | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 | |
| Damowski et al. | Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine | |
| SE8702642D0 (sv) | Lokalt anvendbara, pharmaceutiska beredningar | |
| SE8402098L (sv) | Perfluorkarbonemulsion, framstellning derav samt dess anvendning i terapi | |
| ES2329426T3 (es) | Sistema terapeutico transdermico que contiene un agente parasimpaticomimetico y un agente parasimpaticolitico. | |
| Griswold Jr et al. | CYTOSINE ARABINOSIDE (NSC-63878) | |
| SE8303003D0 (sv) | Medel for att oka antitumorverkan hos antitumormedel | |
| TR200100021T2 (tr) | Kandaki yağ değerlerini etkileyen en az bir etki maddesine sahip bileşim | |
| MX9203374A (es) | Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina. | |
| CO4940430A1 (es) | Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales | |
| Rozencweig et al. | m-AMSA and PALA: two new agents in cancer chemotherapy | |
| MX9203405A (es) | Compuestos activos para usarse en el tratamiento de tumores. | |
| ES2032797T3 (es) | Agente terapeutico para el tratamiento de la enfermedad ulcera peptica. | |
| Jonker et al. | Comparison of the effects of ascorbyl palmitate and L-ascorbic acid on paracetamol-induced hepatotoxicity in the mouse | |
| Valeriote et al. | Dose and interval relationship for the interaction of WR-2721 and nitrogen mustard with normal and malignant cells | |
| Freedman et al. | Cyclic AMP maintenance of rabbit reticulocyte haem and protein synthesis in the presence of ethanol and benzene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |